Comparative Effects of Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines in The Prevention of Genotype-Specific Infection: A Systematic Review and Network Meta-Analysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background Human papillomavirus (HPV) infection is a major global disease burden and the main cause of cervical cancer. Certain HPV genotypes, with are the most common etiologic pathogens and cause a significant disease burden, are being targeted for vaccine development. However, few studies have focused on the comparative effectiveness of the bivalent HPV (2v-HPV), quadrivalent HPV (4v-HPV), and nonavalent HPV (9v-HPV) vaccines against HPV strain-specific infection. This study investigated the comparative effects of these vaccines against genotype-specific infection. Materials and Methods We conducted a pairwise and network meta-analysis of published randomized clinical trials of HPV vaccines according to sex and HPV infection status for nine HPV genotypes (HPV 6/11/16/18/31/33/45/52/58). Results Overall, 10 randomized controlled trials (12 articles) were included in this study. In the network meta-analysis, no statistically significant differences were observed in the prevention of carcinogenic HPV strains (16/18/31/33/45/52/58) between the 2v-HPV and 4v-HPV vaccines in female HPV infection–naïve populations. However, the 9v-HPV vaccine showed a significantly superior effect compared with 2v-HPV and 4v-HPV vaccines in preventing HPV 31/33/45/52/58 infections. Although 2v-HPV and 4v-HPV vaccines provided some cross-protection against HPV 31/33/45/52/58 infections, the effect was significant only on HPV 31 infection. For HPV 16 and 18, neither statistically significant nor small differences were found in the prevention of HPV infection among the 2v-HPV, 4v-HPV, and 9v-HPV vaccines. Conclusion Our study complements previous understanding of how the effect of HPV vaccines differs according to the HPV genotype. This is important because HPV genotype prevalence varies among countries. We advocate for continued efforts in vaccinating against HPV, while public health agencies should consider the difference in the vaccine effect and HPV genotype prevalence when implementing HPV vaccination in public vaccination programs.
Abstract
Background Human papillomavirus (HPV) infection is a major global disease burden and the main cause of cervical cancer. Certain HPV genotypes, with are the most common etiologic pathogens and cause a significant disease burden, are being targeted for vaccine development. However, few studies have focused on the comparative effectiveness of the bivalent HPV (2v-HPV), quadrivalent HPV (4v-HPV), and nonavalent HPV (9v-HPV) vaccines against HPV strain-specific infection. This study investigated the comparative effects of these vaccines against genotype-specific infection. Materials and Methods We conducted a pairwise and network meta-analysis of published randomized clinical trials of HPV vaccines according to sex and HPV infection status for nine HPV genotypes (HPV 6/11/16/18/31/33/45/52/58). Results Overall, 10 randomized controlled trials (12 articles) were included in this study. In the network meta-analysis, no statistically significant differences were observed in the prevention of carcinogenic HPV strains (16/18/31/33/45/52/58) between the 2v-HPV and 4v-HPV vaccines in female HPV infection–naïve populations. However, the 9v-HPV vaccine showed a significantly superior effect compared with 2v-HPV and 4v-HPV vaccines in preventing HPV 31/33/45/52/58 infections. Although 2v-HPV and 4v-HPV vaccines provided some cross-protection against HPV 31/33/45/52/58 infections, the effect was significant only on HPV 31 infection. For HPV 16 and 18, neither statistically significant nor small differences were found in the prevention of HPV infection among the 2v-HPV, 4v-HPV, and 9v-HPV vaccines. Conclusion Our study complements previous understanding of how the effect of HPV vaccines differs according to the HPV genotype. This is important because HPV genotype prevalence varies among countries. We advocate for continued efforts in vaccinating against HPV, while public health agencies should consider the difference in the vaccine effect and HPV genotype prevalence when implementing HPV vaccination in public vaccination programs.
참고문헌 (28)
- Muñoz N, "Epidemiologic classification of human papillomavirus types associated with cervical cancer", N Engl J Med, 348, pp.518~527 (2003)
- Tota JE, "Epidemiology and burden of HPV infection and related diseases : implications for prevention strategies", Prev Med, 53(Suppl 1), pp.S12~S21 (2011)
- de Sanjosé S, "Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology : a meta-analysis", Lancet Infect Dis, 7, pp.453~459 (2007)
- Arbyn M, "Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials", Expert Rev Vaccines, 17, pp.1085~1091 (2018)
- World Health Organization, "WHO position on HPV vaccines", Vaccine, 27, pp.7236~7237 (2009)
- Bruni L, "HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019", Prev Med, 144, pp.106399~ (2021)
- Bergman H, "Comparison of different human papillomavirus(HPV)vaccine types and dose schedules for prevention of HPV-related disease in females and males", Cochrane Database Syst Rev, 2019, pp.CD013479~ (2019)
- Huang R, "The comparative safety of human papillomavirus vaccines : A Bayesian network meta-analysis", J Med Virol, 94, pp.729~736 (2022)
- Ki M, "The economic burden of human papillomavirus infection-associated diseases in the Republic of Korea, 2002-2015", Vaccine, 36, pp.4633~4640 (2018)
- Lumley T, "Network meta-analysis for indirect treatment comparisons", Stat Med, 21, pp.2313~2324 (2002)
- Moher D, "Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement", PLoS Med, 6, pp.e1000097~ (2009)
- Cumpston M, "Updated guidance for trusted systematic reviews : a new edition of the Cochrane handbook for systematic reviews of interventions", Cochrane Database Syst Rev, 10, pp.ED000142~ (2019)
- Higgins JP, "Cochrane handbook for systematic reviews of interventions" (2019), John Wiley & Sons
- Zhu FC, "Efficacy, immunogenicity, and safety of the HPV-16", 18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years : event-triggered analysis of a randomized controlled trial, 2017, pp.6, 12~25
- Konno R, "Efficacy of the human papillomavirus(HPV)-16", 18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women, 2014, pp.10, 1781~1794
- Harper DM, "Sustained efficacy up to 4. 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18 : follow-up from a randomised control trial", Lancet, 367, pp.1247~1255 (2006)
- Szarewski A, "Efficacy of the human papillomavirus(HPV)-16", 18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16, Int J Cancer, pp.2012, 131[DOI]
- Wheeler CM, "Cross-protective efficacy of HPV-16", 18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types : 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial, 2012, pp.13, 100~110
- Brown DR, "The impact of quadrivalent human papillomavirus(HPV; types 6, 11, 16, and 18)L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years", J Infect Dis, 199, pp.926~935 (2009)
- Wheeler CM, "The impact of quadrivalent human papillomavirus(HPV; types 6, 11, 16, and 18)L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years", J Infect Dis, 199, pp.936~944 (2009)
- Castellsagué X, "End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV(types 6, 11, 16, 18)recombinant vaccine in adult women 24-45 years of age", Br J Cancer, 105, pp.28~37 (2011)
- Yoshikawa H, "Efficacy of quadrivalent human papillomavirus(types 6, 11, 16 and 18)vaccine(GARDASIL)in Japanese women aged 18-26 years", Cancer Sci, 104, pp.465~472 (2013)
- Giuliano AR, "Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males", N Engl J Med, 364, pp.401~411 (2011)
- Mikamo H, "Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men : A randomized, phase 3, placebo-controlled study", Vaccine, 37, pp.1651~1658 (2019)
- Huh WK, "Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years : a randomised, double-blind trial", Lancet, 390, pp.2143~2159 (2017)
- Medeiros LR, "Efficacy of human papillomavirus vaccines : a systematic quantitative review", Int J Gynecol Cancer, 19, pp.1166~1176 (2009)
- Villa A, "Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines : Umbrella review of systematic reviews", J Am Dent Assoc, 151, pp.245~254 (2020)
- Serrano B, "Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries(Brazil, Mexico, India and China)", Cancer Epidemiol, 38, pp.748~756 (2014)